Market Cap: $11.67B
CI
Corcept Therapeutics Incorporated
CORT
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $11.67B
Corcept Therapeutics Incorporated ( CORT ) has been making significant strides in the pharmaceutical landscape, particularly in the treatment of serious metabolic and oncological disorders. The compan…
Corcept Therapeutics (Ticker: CORT) has recently made headlines by resubmitting its New Drug Application (NDA) to the FDA for relacorilant, a treatment aimed at Cushing’s syndrome. This strategic move…
Corcept Therapeutics (Ticker: CORT) has made a significant move in the pharmaceutical landscape by resubmitting its New Drug Application (NDA) to the FDA for relacorilant, targeting Cushing’s syndrome…
Corcept Therapeutics (Ticker: CORT) continues to advance its position in the field of metabolic disease treatment by presenting promising data from its recent clinical trials. At the American Diabetes…
Corcept Therapeutics (Ticker: CORT) advances its position in the oncology space following promising trial results for its ovarian cancer drug, Lifyorli. The company's recent announcement highlights a…
Corcept Therapeutics (Ticker: CORT) announces significant advancements in its ovarian cancer treatment, Lifyorli, bolstered by data from a successful Phase 3 trial. The ROSELLA trial's results show ro…
Corcept Therapeutics has released significant long-term survival data from its Phase 2 DAZALS trial for the investigational drug dazucorilant in patients with Amyotrophic Lateral Sclerosis (ALS). The…
Corcept Therapeutics Faces Legal Challenges Over Misleading Drug Trial Information Corcept Therapeutics Incorporated is currently embroiled in multiple class action lawsuits accusing the company of se…
Emerging Legal Challenges for Corcept Therapeutics Amid Clinical Trial Allegations Corcept Therapeutics finds itself embroiled in a series of class action lawsuits that could have significant implicat…
Corcept Therapeutics Faces Class Action Lawsuit Over Drug Approval Misrepresentations Corcept Therapeutics is grappling with multiple class action lawsuits initiated by investors who claim significant…
Corcept Therapeutics Faces Class Action Lawsuits Over Regulatory Misstatements Corcept Therapeutics Incorporated is currently embroiled in legal challenges stemming from allegations of misleading stat…
Corcept Therapeutics Faces Class Action Suit Over Misleading FDA Communications Corcept Therapeutics Incorporated, a biopharmaceutical company focused on developing treatments for metabolic and psychi…
Corcept Therapeutics Faces Class Action Lawsuits Over Regulatory Misrepresentation Corcept Therapeutics Incorporated is currently entangled in multiple class action lawsuits stemming from allegations…
Corcept Therapeutics Faces Class Action Over Misleading Statements on relacorilant Approval Corcept Therapeutics Incorporated is embroiled in legal troubles following the announcement of multiple clas…
Class Action Lawsuit Highlights Corporate Accountability in Biopharmaceutical Sector In a significant development for Corcept Therapeutics Incorporated, two law firms have announced class action lawsu…
Class Action Lawsuit Looms for Corcept Therapeutics Amid Clinical Trial Controversy Corcept Therapeutics Incorporated, a company focused on developing innovative treatments for cancer and related diso…
Corcept Therapeutics Faces Legal Challenges Over Misleading Statements on Relacorilant Corcept Therapeutics Incorporated finds itself embroiled in a securities class action lawsuit due to allegations…
### Legal Troubles for Corcept Therapeutics: Class Action Lawsuits Emerge Corcept Therapeutics Inc. finds itself in substantial legal turmoil following the announcement of multiple class action lawsui…
Corcept Therapeutics Faces Class Action Lawsuits Over Misleading Statements on Relacorilant Corcept Therapeutics Incorporated finds itself at the center of two class action lawsuits, both filed on Mar…
Corcept Therapeutics Faces Legal Challenges Over Alleged Misleading Claims Corcept Therapeutics Incorporated is currently embroiled in serious legal difficulties with two separate class action lawsuit…
Corcept Therapeutics Faces Class Action Lawsuits Over Misleading Claims Regarding Relacorilant Corcept Therapeutics Incorporated (NASDAQ: CORT) is currently encountering significant legal challenges a…
Class Action Lawsuit Targets Corcept Therapeutics Over Regulatory Misrepresentation A class action lawsuit has surfaced against Corcept Therapeutics Inc., spotlighting troubling allegations about the…
Corcept Therapeutics Faces Class Action Lawsuit Over Relacorilant Claims Corcept Therapeutics Inc. stands at the center of a class action lawsuit filed by Robbins LLP, which represents investors who p…
Corporate Transparency Under Scrutiny at Corcept Therapeutics Corcept Therapeutics Inc. is currently embroiled in a class action lawsuit stemming from allegations of misleading investors regarding the…
Corcept Therapeutics Faces Class Action Lawsuit Over NDA Process for Relacorilant Corcept Therapeutics Incorporated is currently embroiled in legal challenges as Robbins Geller Rudman & Dowd LLP initi…
Corcept faces a securities class action after the FDA finds gaps in evidence for its lead drug relacorilant. Regulatory Setback Sparking Class Action Robbins Geller Rudman & Dowd LLP is filing a class…
Corcept seeks court order to block Teva label it says would induce patented dosing Label wording, not chemistry, is at the heart of Corcept Therapeutics’ latest legal challenge against Teva Pharmaceut…
Label wording for generic Korlym draws Corcept into court fight over patented dosing method Corcept Therapeutics is asking a court to block Teva Pharmaceutical Industries from using proposed labeling…
Court Fight Over Korlym Labeling Intensifies Corcept Therapeutics says Teva Pharmaceuticals’ proposed label for a generic version of Korlym (mifepristone) would effectively induce physicians to use a…
FDA CRL Halts Approval Path for Relacorilant Corcept Therapeutics is facing a regulatory setback after the U.S. Food and Drug Administration issues a Complete Response Letter for its New Drug Applicat…
Regulatory disclosure probes target Corcept over relacorilant communications Regulatory and shareholder-rights law firms are opening parallel investigations into Corcept Therapeutics after the U.S. Fo…
Regulatory setback for relacorilant spurs shareholder probes into Corcept Regulatory and legal scrutiny intensifies around Corcept Therapeutics after two national law firms say they are investigating…
Regulatory setback forces reassessment of relacorilant development plans Corcept Therapeutics faces a fresh regulatory hurdle after the U.S. Food and Drug Administration issues a Complete Response Let…
Headline: Two law firms open probes into Corcept over relacorilant FDA response Main inquiry into corporate disclosures Two U.S. securities firms announce parallel investigations into Corcept Therapeu…
Corcept Therapeutics Faces Regulatory Setback with FDA's Response on Relacorilant Corcept Therapeutics Incorporated encounters a significant hurdle in its drug development journey as the U.S. Food and…
Corcept Therapeutics Faces Scrutiny Following FDA Setback on Relacorilant Corcept Therapeutics Incorporated, a biopharmaceutical company specializing in treatments for disorders associated with cortis…
Corcept Therapeutics Faces Regulatory Setback with FDA’s Complete Response Letter Corcept Therapeutics Incorporated encounters a significant regulatory hurdle as it receives a Complete Response Letter…
Corcept Therapeutics Faces Regulatory Setback as FDA Issues Complete Response Letter for Relacorilant Corcept Therapeutics Incorporated finds itself in troubled waters following a significant regulato…
Corcept Therapeutics Faces Scrutiny After FDA's Complete Response Letter on Relacorilant Corcept Therapeutics Incorporated is currently navigating turbulent waters following a significant setback in i…
Innovative Solutions for Endocrine Disorders: Crinetics Pharmaceuticals Advances Atumelnant Research Crinetics Pharmaceuticals Inc. is making significant strides in addressing congenital adrenal hyper…
Emerging Solutions in Endocrine Disorders: Crinetics Pharmaceuticals Advances Atumelnant Development Crinetics Pharmaceuticals Inc. is making strides in the treatment of endocrine disorders, particula…
Corcept Therapeutics: Strengthening Financial Resilience Amidst Industry Challenges Corcept Therapeutics, a prominent player in the biotechnology sector, is currently navigating a landscape marked by…
Corcept Therapeutics Faces Setback Following FDA Rejection of Key Drug Corcept Therapeutics, a biopharmaceutical company focused on innovative treatments for Cushing's syndrome and other conditions, g…
Corcept Therapeutics: Insider Trading Raises Questions on Executive Confidence Corcept Therapeutics, a company dedicated to developing innovative treatments for severe metabolic and psychiatric disord…
Corcept Therapeutics' Insider Trading Raises Questions on Company Outlook Corcept Therapeutics, a company focused on developing innovative treatments for severe metabolic and psychiatric disorders, re…
### Insider Transactions Shine Light on Corcept Therapeutics' Strategic Direction Corcept Therapeutics, a key player in the development of innovative treatments for severe metabolic and psychiatric di…
Corcept Therapeutics Faces Insider Trading Scrutiny Amid Ongoing Developments Corcept Therapeutics is currently in the spotlight following a notable insider sale conducted by Chief Development Officer…
Insider Transactions and Their Implications for Corcept Therapeutics Corcept Therapeutics, a company dedicated to developing innovative treatments for serious health conditions, particularly in the ca…
Corcept Therapeutics Faces Scrutiny Over Insider Sale In a recent development, William Guyer, the Chief Development Officer of Corcept Therapeutics, has made headlines following his sale of 10,000 sha…
Corcept Therapeutics: Navigating Market Sentiment Amid Short Selling Trends Corcept Therapeutics Inc., a leader in the development of treatments for severe metabolic and psychiatric disorders, is curr…